Stockscreener 앱 받기
849.04
2.50%
20.69
시간 외 거래:
849.04
전일 마감가:
$828.35
열려 있는:
$849.03
하루 거래량:
235.93K
Relative Volume:
0.66
시가총액:
$52.80B
수익:
$4.16B
순이익/손실:
$1.29B
주가수익비율:
43.35
EPS:
19.5837
순현금흐름:
$734.26M
1주 성능:
+6.18%
1개월 성능:
+20.26%
6개월 성능:
+0.64%
1년 성능:
+42.41%
1일 변동 폭
$842.93
$852.28
1주일 범위
$790.82
$852.28
52주 변동 폭
$510.06
$934.62
알제넥스 NV ADR Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-12-18 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 재개 | Truist | Buy |
| 2025-09-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2025-01-17 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-11-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
Argenx SE stock (NL0010832176): Is Vyvgart's rare disease dominance strong enough to unlock new upsi - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. momentum strong enough to unlock new upside? - AD HOC NEWS
argenx SE (MEX:ARGXN) Competitors 2026 - GuruFocus
Who's Buying or Selling argenx SE (MEX:ARGXN) Stock Today? - GuruFocus
argenx SE (MEX:ARGXN) Stock Price, Trades & News - GuruFocus
argenx SE (MEX:ARGXN)Valuation Measures & Financial Statistics - GuruFocus
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP - ChartMill
ARGX Stock Price, Quote & Chart | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. expansion strong enough to unlock new upside? - AD HOC NEWS
Argenx shares see TD Cowen reiterate Buy on Vyvgart strength By Investing.com - Investing.com South Africa
Argenx shares see TD Cowen reiterate Buy on Vyvgart strength - Investing.com
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. dominance now the key growth lever? - AD HOC NEWS
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026 By Investing.com - Investing.com South Africa
Argenx Leads Turnover Charts with $250 Million in Trades, Concealing a Slight Decline During Sector Shifts - Bitget
ARGX Technical Analysis | Trend, Signals & Chart Patterns | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP - GlobeNewswire Inc.
Stocks Showing Improved Relative Strength: argenx ADR - Investor's Business Daily
Why Is Viridian Therapeutics Stock Sinking Monday? - Sahm
Argenx SE Stock: Biotech Leader in Autoimmune Therapies Driving Investor Interest with Strong Growth - AD HOC NEWS
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Is Viridian Therapeutics Stock Falling Monday? - Sahm
argenx SE (HAM:1AEA) Stock Price, Trades & News - GuruFocus
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx SE Stock Faces Pressure Amid Pipeline Setbacks and Market Volatility in Biotech Sector - ad-hoc-news.de
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Form 6K argenx NV ADR For: 20 March By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 20 March - Investing.com
argenx announces Annual General Meeting of Shareholders on May 6, 2026 - ChartMill
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Argenx SE stock faces pressure as Iron Triangle Partners trims position amid biotech sector watchlis - AD HOC NEWS
TD Cowen reiterates argenx stock Buy rating on growth outlook By Investing.com - Investing.com India
TD Cowen reiterates argenx stock Buy rating on growth outlook - Investing.com
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’ - Investing.com South Africa
Deutsche Bank upgrades argenx stock to Buy on valuation appeal By Investing.com - Investing.com South Africa
Deutsche Bank upgrades argenx stock to Buy on valuation appeal - Investing.com India
Forecasting The Future: 16 Analyst Projections For argenx - Sahm
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached - Finviz
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock - Finviz
Argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - marketscreener.com
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - ChartMill
Empowering Investor Success - Morningstar
Argenx Benefits From Strong Growth for Vyvgart; Pipeline Continues to Make Progress - Morningstar
Oppenheimer raises argenx stock price target to $1,060 on sales growth - Investing.com
RBC Capital Adjusts argenx SE ADR PT to $890 From $925, Maintains Outperform Rating - marketscreener.com
ARGENX : Goldman Sachs gives a Buy rating - marketscreener.com
Citizens raises argenx stock price target on ocular MG results - Investing.com
ARGENX : Deutsche Bank reiterates its Neutral rating - marketscreener.com
argenx Q4 2025 slides: first profitable year, 90% revenue surge By Investing.com - Investing.com Australia
Stifel cuts argenx stock price target to $1,227 on valuation By Investing.com - Investing.com South Africa
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.27%
0.99%
자본화:
|
볼륨(24시간):